查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401841

2030 年迷幻藥市場預測：按產品類型、藥物類型、應用、最終用戶和地區分類的全球分析

Psychedelic Market Forecasts to 2030 - Global Analysis By Product, Drug Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球迷幻藥物市場規模將達到 8 億美元，預計 2030 年將達到 22.1 億美元，預測期內複合年成長率為 15.4%。

致幻劑，也稱為致幻劑，是一種改變知覺、情緒和各種認知過程的物質。致幻劑通常會引起意識的深刻變化，導致思想、情緒和感覺的變化。幾個世紀以來，致幻劑一直在各種文化中用於宗教、精神和薩滿目的。提高創造力、注意力和情緒。

負責全球公共衛生的聯合國專門機構世界衛生組織的報告估計，每年約有 5% 的美國人患有創傷後壓力症候群 (PTSD)。

治療的可能性正在被認知到

全球範圍內心理健康問題的增加和現有治療方法的不足促使人們尋找新的有效的治療性介入。此類研究的積極成果和有希望的結果將有助於改變人們對迷幻藥的看法，從濫用物質轉變為潛在的治療藥物，從而增加研究人員、醫療保健專業人員和製藥行業的興趣。此外，人們對迷幻藥潛在治療益處的認知和教育的提高導致了社會態度的變化，推動了市場的成長。

缺乏標準化

臨床試驗缺乏標準化方案導致試驗設計有差異，且難以比較和解釋不同試驗的結果。為了安全有效地使用迷幻物質，確定適當的給藥和給藥方法非常重要。如果沒有標準化的指南，最佳給藥尚不清楚，可能會導致安全問題和次優的治療結果。這一因素阻礙了市場的拓展。

新治療模式的興起

人們對裸蓋菇素和搖頭丸等致幻物質的治療潛力的興趣和研究不斷成長，引發了大量的臨床試驗。這些臨床試驗的正面結果引起了人們對迷幻藥輔助性治療的關注和支持。社會對心理健康態度的改變以及對傳統精神科治療局限性的認知導致了人們對迷幻藥的看法發生了轉變。此外，倡導團體和患者的證詞在提高人們對心理治療潛在益處的認知方面發揮著重要作用。這些因素的結合正在創造一個有利於迷幻藥物市場成長的環境。

醫學功效與研究挑戰

主要研究挑戰之一是給藥和給藥技術的標準化。在致幻劑/藥物可以廣泛用作治療或藥物之前，它們必須在臨床試驗中通過嚴格的安全性和有效性測試。如果精神藥物研究缺乏科學嚴謹性或被視為不確定，公眾的不信任和懷疑可能會增加。除非有足夠的證據證明治療效果，否則保險公司可能不願意支付迷幻治療費用。它還減少了患者可用的替代治療的多樣性。市場需求受到這些變數的阻礙。

COVID-19 的影響

COVID-19 的爆發對迷幻藥市場產生了負面影響。這種流行病阻礙了致幻藥物的研究和臨床試驗的進展。封鎖、旅行限制和麵對面會議的限制導致研究和臨床試驗的延誤。金融市場經歷了早期的起伏，改變了包括迷幻劑在內的各個階段的投資者情緒。此外，知識的增加和對心理健康態度的改變為後疫情時代迷幻治療的接受和採用創造了有利的環境。

裸蓋菇素預計將在預測期內成為最大的細分市場

裸蓋菇素領域預計將出現良好的成長。裸蓋菇素主要因其致幻作用而聞名，可引起知覺、感官體驗和意識的變化。人們認為它透過影響與情緒調節和情緒處理相關的神經途徑來發揮作用。一些研究顯示出有希望的結果，裸蓋菇素輔助治療可顯著減輕憂鬱症狀並改善情緒健康。減少焦慮、增加創造力、緩解頭痛和增強正念等好處正在推動這一領域的需求。

恐慌症產業預計在預測期內複合年成長率最高

由於其綜合治療和情緒處理的增強，預計恐慌症領域在預測期內將出現最高的複合年成長率。迷幻體驗通常伴隨著高度的內省和正念感。這種增強的意識可以幫助個人面對和處理他們的恐懼，使他們更能接受自己的情緒和經驗。許多迷幻藥，包括裸蓋菇素和LSD，主要與大腦中的血清素受體相互作用。這可以暫時改變個人體驗和處理恐懼的方式，可能有助於打破恐慌的循環。

佔有率最大的地區

預計亞太地區在預測期內將佔據最大的市場佔有率。亞太地區對迷幻藥物研發的興趣日益濃厚，特別是在心理健康領域。此外，人們對這一領域的迷幻投資和新興企業越來越感興趣。印度在市場佔有率和收入方面領先迷幻藥物產業。隨著該地區擴大接受這些治療憂鬱症的藥物，而快速的研發刺激了該行業，這一優勢預計將持續下去。

複合年成長率最高的地區：

由於研究試驗的擴大和法規環境的變化，預計北美在預測期內將出現最高的複合年成長率。在北美開展業務的主要企業包括輝瑞 (Pfizer)、Theron Pharmaceuticals、Cybin、Jazz Pharmaceuticals 和 Pharmacer Holdings。在北美，憂鬱症精神疾病的盛行率正在增加。為了教育加拿大人了解精神疾病的現實，加拿大政府每週都會舉辦一次精神疾病宣導宣傳活動。由於精神疾病的增加和意識計劃的加強，預計北美將進一步成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球迷幻藥市場：按產品

  • 麥角酸二乙醯胺 (LSD)
  • 3,4-亞甲基二氧基甲基安非他命（搖頭丸）
  • 苯環己哌啶
  • γ-羥基丁酸 (GHB)
  • 乙胺
  • 死藤水
  • 丹參
  • 裸蓋菇素

第6章全球迷幻藥市場：依藥物類型

  • 注射致幻劑
  • 口服致幻劑
  • 經皮致幻劑
  • 直腸致幻劑
  • 鼻致幻劑

第7章全球致幻劑市場：依應用分類

  • 重度憂鬱症
  • 抗治療性憂鬱症
  • 恐慌症
  • 創傷後壓力症候群
  • 鴉片上癮
  • 發作性睡病
  • 其他用途

第8章全球迷幻藥市場：依最終用戶分類

  • 專科診所
  • 醫院
  • 居家照護
  • 其他最終用戶

第9章全球迷幻藥市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Johnson & Johnson（J&J）
  • Enveric Biosciences
  • Ceruvia Lifesciences
  • Apex Labs
  • Numinus Wellness Inc
  • Jazz Pharmaceuticals
  • Cybin Inc
  • Revive Therapeutics
  • Psychedelic Water
  • PharmaTher Holdings Limited
  • MindMed
  • Compass Pathways
  • Field Trip Health
  • ATAI Life Sciences
  • Hikma Pharmaceuticals PLC
  • Verrian
  • Celon Pharma SA
  • NRX Pharmaceuticals
  • Rose Hill Company
  • Psycheceutical Bioscience Inc
Product Code: SMRC24361

According to Stratistics MRC, the Global Psychedelic Market is accounted for $0.8 billion in 2023 and is expected to reach $2.21 billion by 2030 growing at a CAGR of 15.4% during the forecast period. Psychedelics, also known as hallucinogens, are a class of substances that alter perception, mood, and various cognitive processes. They often induce profound changes in consciousness, leading to altered thoughts, feelings, and sensory perceptions. Psychedelics have been used for centuries in various cultures for religious, spiritual, or shamanic purposes. It enhances creativity, focus, and mood.

According to the report by World Health Organization, a specialized agency of the United Nations responsible for international public health, it was estimated that, approximately 5% of Americans suffer from PTSD each year.

Market Dynamics:

Driver:

Growing acceptance of the therapeutic potential

The global increase in mental health issues and the inadequacy of existing treatments have led to a search for novel and effective therapeutic interventions. Positive outcomes and promising results from these studies have helped change the perception of psychedelics from substances of abuse to potential therapeutic agents, stimulating interest from researchers, healthcare professionals, and the pharmaceutical industry. Additionally, increased awareness and education about the potential therapeutic benefits of psychedelics have contributed to changing societal attitudes which is thereby fuelling the market growth.

Restraint:

Lack of standardization

Lack of standardized protocols for clinical trials can lead to variability in study designs, making it challenging to compare and interpret results across different trials. Determining appropriate dosages and administration methods for psychedelic substances is critical for their safe and effective use. Without standardized guidelines, there may be a lack of clarity on optimal dosages, leading to potential safety concerns or suboptimal therapeutic outcomes. This element is hindering the market from expansion.

Opportunity:

Rise in new treatment paradigms

Increased scientific interest and research in the therapeutic potential of psychedelic substances, such as psilocybin and MDMA, have led to numerous clinical trials. Positive results from these trials have garnered attention and support for psychedelic-assisted therapies. Evolving societal attitudes towards mental health and a growing acknowledgment of the limitations of traditional psychiatric treatments have shifted perceptions of psychedelics. Also, advocacy groups and patient testimonials have played a crucial role in raising awareness about the potential benefits of psychedelic-assisted therapies. The convergence of these factors has created a conducive environment for the growth of the psychedelic market

Threat:

Medical efficacy & research challenges

One of the primary research problems is to standardize dose and delivery techniques. Before psychedelic drugs are extensively utilised for therapeutic or medicinal purposes, they need to pass stringent safety and effectiveness testing in clinical studies. Public mistrust and scepticism may increase if studies on psychedelics are seen as missing scientific rigour or being inconclusive. Insurance companies could be hesitant to pay for psychedelic therapies if there isn't enough proof of their therapeutic benefits. It also reduces the variety of therapeutic alternatives that patients can choose from. The market demand is hampered by these variables.

COVID-19 Impact

The COVID-19 pandemic had negatively impacted the psychedelic market. The epidemic hampered the advancement of psychedelic research investigations and clinical trials. Lockdowns, travel restrictions, and limits on face-to-face meetings caused delays to research efforts and trials. Financial markets experienced volatility during the early phases, leading to changes in investor sentiment across various sectors, including psychedelics. In addition, a more suitable climate for the acceptance and incorporation of psychedelic treatments in the post-pandemic age was created by growing knowledge and shifting attitudes towards mental health.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is estimated to have a lucrative growth. Psilocybin is primarily known for its psychedelic effects, inducing altered perceptions, sensory experiences, and changes in consciousness. It is believed to work by influencing neural pathways associated with mood regulation and emotional processing. Some studies have shown promising results, with psilocybin-assisted therapy leading to significant reductions in depressive symptoms and improved emotional well-being. Its benefits namely anxiety reduction, enhancing creativity, headache relief and heightened mindfulness fuels the segment demand.

The panic disorders segment is expected to have the highest CAGR during the forecast period

The panic disorders segment is anticipated to witness the highest CAGR growth during the forecast period, due to its integrated therapies and enhanced emotional processing. The psychedelic experience often involves a heightened sense of introspection and mindfulness. This increased awareness may help individuals confront and process their fears, fostering a greater acceptance of emotions and experiences. Many psychedelics, including psilocybin and LSD, primarily interact with serotonin receptors in the brain. This can lead to a temporary shift in the way individuals experience and process fear, potentially helping to break the cycle of panic.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. There is a growing interest in psychedelic research and development in the Asia-Pacific region, especially in the area of mental health. Additionally, there has been an increase in interest in psychedelic investments and start-ups in the area. In terms of market share and income, India leads the psychedelic drug industry. This dominance is expected to persist as the region's acceptance of these medications for the treatment of depression grows and the industry is being stimulated by rapid research development.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to expanding research trials and shifting regulatory environment. It is home for major key players such as Pfizer Inc, Celon Pharmaceuticals, Cybin Corp, Jazz Pharmaceuticals, and PharmaTher Holdings. There is a rise in the prevalence of mental illnesses like depression in North America. To further inform Canadians on the realities of mental illness, the government of Canada also runs a weekly campaign to raise awareness of the condition. North America is further anticipated to witness growth with rising mental illness and growing awareness programs.

Key players in the market:

Some of the key players profiled in the Psychedelic Market include Johnson & Johnson (J&J), Enveric Biosciences, Ceruvia Lifesciences, Apex Labs, Numinus Wellness Inc, Jazz Pharmaceuticals, Cybin Inc, Revive Therapeutics, Psychedelic Water, PharmaTher Holdings Limited, MindMed, Compass Pathways, Field Trip Health, ATAI Life Sciences, Hikma Pharmaceuticals PLC, Verrian, Celon Pharma SA, NRX Pharmaceuticals, Rose Hill Company and Psycheceutical Bioscience Inc.

Key Developments:

In November 2023, Psycheceutical Bioscience Inc announced the launch of a community crowd funding campaign on Wefunder. The campaign is currently open to all investors, and serves as the next step in Psycheceutical's mission to revolutionize mental health treatment by bringing safe, effective, and accessible psychedelic therapies to patients worldwide using precise drug delivery technologies.

In October 2023, The viral brand Psychedelic Water has launched a new product line: Psychedelic Good Mood Mix. This new product takes Psychedelic Water's award-winning kava-based alcohol alternative and brings it to a new format: a powder drink mix. Psychedelic Good Mood Mix's powder format is lightweight, making it highly portable.

In August 2023, Rose Hill Company, the leading cultivator, supplier and exporter of premium psilocybin products and biomass in Jamaica, celebrates the premier of their psychedelic wellness program, ONE Retreats, and the launch of their newest psilocybin product- the PATOO gummy. These milestones strengthen Rose Hill's total business and prime the Company for U.S. expansion.

Products Covered:

  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Etamine
  • Ayahuasca
  • Salvia
  • Psilocybin

Drug Types Covered:

  • Injectable Psychedelic Drugs
  • Oral Psychedelic Drugs
  • Transdermal Psychedelic Drugs
  • Rectal Psychedelic Drugs
  • Nasal Psychedelic Drugs

Applications Covered:

  • Major Depressive Disorder
  • Resistant Depression
  • Panic Disorder
  • Post-Traumatic Stress Disorder
  • Opiate Addiction
  • Narcolepsy
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Hospitals
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Psychedelic Market, By Product

  • 5.1 Introduction
  • 5.2 Lysergic Acid Diethylamide (LSD)
  • 5.3 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • 5.4 Phencyclidine
  • 5.5 Gamma Hydroxybutyric Acid (GHB)
  • 5.6 Etamine
  • 5.7 Ayahuasca
  • 5.8 Salvia
  • 5.9 Psilocybin

6 Global Psychedelic Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Injectable Psychedelic Drugs
  • 6.3 Oral Psychedelic Drugs
  • 6.4 Transdermal Psychedelic Drugs
  • 6.5 Rectal Psychedelic Drugs
  • 6.6 Nasal Psychedelic Drugs

7 Global Psychedelic Market, By Application

  • 7.1 Introduction
  • 7.2 Major Depressive Disorder
  • 7.3 Resistant Depression
  • 7.4 Panic Disorder
  • 7.5 Post-Traumatic Stress Disorder
  • 7.6 Opiate Addiction
  • 7.7 Narcolepsy
  • 7.8 Other Applications

8 Global Psychedelic Market, By End User

  • 8.1 Introduction
  • 8.2 Specialty Clinics
  • 8.3 Hospitals
  • 8.4 Homecare
  • 8.5 Other End Users

9 Global Psychedelic Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Johnson & Johnson (J&J)
  • 11.2 Enveric Biosciences
  • 11.3 Ceruvia Lifesciences
  • 11.4 Apex Labs
  • 11.5 Numinus Wellness Inc
  • 11.6 Jazz Pharmaceuticals
  • 11.7 Cybin Inc
  • 11.8 Revive Therapeutics
  • 11.9 Psychedelic Water
  • 11.10 PharmaTher Holdings Limited
  • 11.11 MindMed
  • 11.12 Compass Pathways
  • 11.13 Field Trip Health
  • 11.14 ATAI Life Sciences
  • 11.15 Hikma Pharmaceuticals PLC
  • 11.16 Verrian
  • 11.17 Celon Pharma SA
  • 11.18 NRX Pharmaceuticals
  • 11.19 Rose Hill Company
  • 11.20 Psycheceutical Bioscience Inc

List of Tables

  • Table 1 Global Psychedelic Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Psychedelic Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Psychedelic Market Outlook, By Lysergic Acid Diethylamide (LSD) (2021-2030) ($MN)
  • Table 4 Global Psychedelic Market Outlook, By 3,4-MethylEnedioxyMethamphetamine (Ecstasy) (2021-2030) ($MN)
  • Table 5 Global Psychedelic Market Outlook, By Phencyclidine (2021-2030) ($MN)
  • Table 6 Global Psychedelic Market Outlook, By Gamma Hydroxybutyric Acid (GHB) (2021-2030) ($MN)
  • Table 7 Global Psychedelic Market Outlook, By Etamine (2021-2030) ($MN)
  • Table 8 Global Psychedelic Market Outlook, By Ayahuasca (2021-2030) ($MN)
  • Table 9 Global Psychedelic Market Outlook, By Salvia (2021-2030) ($MN)
  • Table 10 Global Psychedelic Market Outlook, By Psilocybin (2021-2030) ($MN)
  • Table 11 Global Psychedelic Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 12 Global Psychedelic Market Outlook, By Injectable Psychedelic Drugs (2021-2030) ($MN)
  • Table 13 Global Psychedelic Market Outlook, By Oral Psychedelic Drugs (2021-2030) ($MN)
  • Table 14 Global Psychedelic Market Outlook, By Transdermal Psychedelic Drugs (2021-2030) ($MN)
  • Table 15 Global Psychedelic Market Outlook, By Rectal Psychedelic Drugs (2021-2030) ($MN)
  • Table 16 Global Psychedelic Market Outlook, By Nasal Psychedelic Drugs (2021-2030) ($MN)
  • Table 17 Global Psychedelic Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Psychedelic Market Outlook, By Major Depressive Disorder (2021-2030) ($MN)
  • Table 19 Global Psychedelic Market Outlook, By Resistant Depression (2021-2030) ($MN)
  • Table 20 Global Psychedelic Market Outlook, By Panic Disorder (2021-2030) ($MN)
  • Table 21 Global Psychedelic Market Outlook, By Post-Traumatic Stress Disorder (2021-2030) ($MN)
  • Table 22 Global Psychedelic Market Outlook, By Opiate Addiction (2021-2030) ($MN)
  • Table 23 Global Psychedelic Market Outlook, By Narcolepsy (2021-2030) ($MN)
  • Table 24 Global Psychedelic Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Psychedelic Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Psychedelic Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 27 Global Psychedelic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Psychedelic Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 29 Global Psychedelic Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.